Monica Rinaldi gained her B.S. degree in biology with full award and residency in biotechnology with honours at the University of Rome “La Sapienza.” From 1996 to 2001, she was appointed as an Assistant Professor of general pathology, School of Medicine, and as a Professor of molecular biology, School of Engineering (1999-2000). Since 2001, she serves as a Research Scientist at the Department of Biomedicine, National Research Council (CNR). At present, Dr. Rinaldi is the Head of the Medical Biotechnology Unit and a Member of the institute committee at the Institute of Translational Pharmacology, CNR. Her major scientific areas include molecular pathology, experimental oncology, and immunotherapy. Her research interests focus on preclinical protocols of genetic immunization against tumor antigens, combined therapeutic protocols (immunochemotherapy), development of innovative medicinal products, and protocols for advanced therapies (DNA vaccination and gene therapy). Her scientific activity is documented in more than 50 articles in extenso, published in peer-reviewed journals with impact factor, and indexed in PubMed. She is the author of several book chapters and invited reviews. She is coinventor of US patents (USPTO) and Principal Investigator of several grants related to biotechnology applications in medicine. In 2011, Dr. Rinaldi was an Associate Editor of the Journal of Alzheimer Disease. She is currently a Member of the Editorial Boards of the Novus International Journal of Biotechnology & Bioscience, Journal of Chemical Rapid Communications, Biological and Biomedical Reports, Biologia Moderna, ISRN Preventive Medicine, Immunity and Diseases; a Referee of Cancer Letters, Vaccine, Cellular Immunology, Cancer Immunology Immunotherapy, Acta Biochimica et Biophysica Sinica, and Journal of the Royal Society Interface.
Biography Updated on 30 October 2012